Can-Fite BioPharma Ltd. - American Depositary Receipt (CANF)
AMEX AMEX Primary Summary
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
CanFite Biopharma (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
CanFite Biopharma (CANF) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Can-Fite BioPharma Ltd. - American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SE Sima Elimelech Activest Wealth Management | 10 | $31 | $28.7 | -$2.3 | -7.42% |
Can-Fite BioPharma Ltd. - American Depositary Receipt (CANF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Can-Fite BioPharma Ltd. - American Depositary Receipt ever had a stock split?
Can-Fite BioPharma Ltd. - American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Pnina Fishman CEO | AMEX Exchange | 13471N201 CUSIP |
| IL Country | 5 Employees | 10 May 2019 Last Dividend | 5 Jan 2026 Last Split | - IPO Date |
Overview
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company based in Israel, focusing on the development of orally bioavailable small molecule therapeutic products aimed at treating a variety of conditions including cancer, liver inflammatory diseases, and erectile dysfunction. The company has evolved from its original inception as Can-Fite Technologies Ltd., undergoing a name change in January 2001 to better reflect its focus on biopharmaceuticals. Since its establishment in 1994, Can-Fite BioPharma Ltd. has pursued the advancement of innovative treatments, leveraging its research and development capabilities to meet the needs of patients worldwide. Through strategic license and collaboration agreements, including partnerships with CMS Medical and Univo Pharmaceuticals, Can-Fite is committed to discovering and developing effective treatment options for challenging diseases.
Products and Services
- Piclidenoson
This leading drug candidate has successfully completed Phase III clinical trials for the treatment of psoriasis. Piclidenoson represents Can-Fite's commitment to addressing autoimmune and inflammatory conditions by targeting specific cellular mechanisms. The company’s collaboration with CMS Medical aims to further develop, manufacture, and commercialize this promising therapy.
- Namodenoson
Currently undergoing a Phase III clinical trial for liver cancer, Namodenoson also demonstrates versatility with ongoing trials in pancreatic cancer (Phase IIa) and metabolic associated steatohepatitis (Phase IIb). This broad-spectrum candidate showcases Can-Fite’s approach to cancer treatment and liver disease management through innovative, targeted therapies.
- CF602
In the pre-clinical trial phase, CF602 is being explored as a potential treatment for erectile dysfunction. This investigational drug underscores the company's expansion into different therapeutic areas, applying its core technology platform to address unmet medical needs in sexual health.
- Predictive Biomarker Blood Test Kit for A3AR
Can-Fite is also developing a commercial predictive biomarker blood test kit aimed at identifying the A3 adenosine receptor (A3AR) presence, which is pivotal in the mechanism of action of the company's drug candidates. This development highlights the company’s commitment to precision medicine, ensuring that the right treatment can be matched to the right patients based on specific biological markers.
- Collaboration Agreement with Univo Pharmaceuticals
This partnership is focused on identifying and co-developing specific formulations of cannabis components for the treatment of a range of conditions, including cancer, inflammatory, autoimmune, and metabolic diseases. This collaboration underlines Can-Fite's dedication to exploring novel therapeutic avenues and harnessing the potential of natural compounds in medicine.
